Scientists have made an important discovery that sheds light on how aspirin may play a vital role in reducing the spread of certain types of cancer. Published in Nature, the research unveils the mechanism behind aspirin’s ability to stimulate the immune system to combat metastasis—the process where cancer cells break away from their original tumour and spread to other parts of the body.

This revelation is expected to enhance ongoing clinical trials and pave the way for more targeted therapies aimed at preventing the spread of cancer.

Metastasis remains one of the deadliest aspects of cancer, responsible for 90% of cancer-related deaths. While early-stage tumours are often treatable through surgery or other interventions, the danger lies in micrometastases—tiny clusters of cancer cells that seed themselves in distant organs and lie dormant before eventually growing into life-threatening secondary tumours.

Aspirin’s potential to disrupt this process has been observed in previous studies, where patients taking low-dose aspirin daily experienced reduced cancer spread, particularly in breast, bowel, and prostate cancers. However, until now, the exact biological mechanism underpinning these observations remained elusive.

The breakthrough emerged serendipitously during investigations into how the immune system responds to metastasis. Researchers focused on understanding why lone metastatic cancer cells are more vulnerable to immune attack than cells in primary tumours, where immunosuppressive environments are often well-established. In a landmark study involving mice, they screened 810 genes and identified 15 that influenced cancer metastasis. Among them was a gene responsible for producing a protein called ARHGEF1, which was found to suppress T cell immunity—a critical line of defence against metastatic cancer cells.

ARHGEF1 plays a pivotal role by dampening the activity of T cells, immune cells capable of recognising and killing rogue cancer cells. Mice lacking this gene demonstrated significantly reduced metastasis to the lungs and liver across various cancers.

The findings prompted researchers to delve deeper into how ARHGEF1 is activated, leading to an unexpected discovery: the protein is switched on by thromboxane A2 (TXA2), a clotting factor commonly associated with blood platelets.

This connection between TXA2 and immune suppression was an eye-opener for scientists, particularly given aspirin’s established role in inhibiting TXA2 production. Aspirin’s anti-clotting properties have long been used to prevent heart attacks and strokes, and now it appears this same mechanism could be integral to its anti-metastatic effects. By reducing TXA2 levels, aspirin effectively frees T cells from suppression, enabling them to target and destroy metastatic cancer cells more efficiently.

To validate their hypothesis, researchers used mouse models of melanoma. Mice treated with aspirin showed a marked reduction in metastasis compared to control groups, confirming that aspirin’s impact was directly linked to its ability to release T cells from TXA2-mediated suppression. This discovery opens up exciting possibilities for developing new drugs that could mimic aspirin’s anti-metastatic properties without its associated risks.

While the findings offer hope for improved cancer treatments, experts caution against premature self-medication with aspirin. Although widely available and inexpensive, aspirin can cause serious side effects in certain individuals, including stomach ulcers and bleeding complications. Clinical trials are underway to determine how aspirin can be used safely and effectively to prevent cancer spread, but researchers emphasise the importance of consulting healthcare professionals before starting any aspirin regimen.

The implications of this study are immense. Aspirin’s ability to target TXA2 provides a promising therapeutic window during early metastasis when cancer cells are most vulnerable to immune attack. Unlike immunotherapies designed for advanced metastatic cancers, aspirin could be strategically deployed to prevent recurrence in patients who have undergone successful treatment for early-stage cancers but remain at risk of relapse.

This discovery also brings hope for more accessible treatments globally. Aspirin and similar drugs targeting TXA2 could offer a cost-effective alternative to expensive antibody-based therapies, making advanced cancer care available to underserved populations. The affordability and widespread availability of aspirin could revolutionise cancer prevention strategies, particularly in low-resource settings.

Looking ahead, researchers plan to collaborate with clinical trial programmes exploring aspirin’s role in preventing early-stage cancers from returning. These trials aim to identify which patients are most likely to benefit from aspirin therapy while minimising risks associated with its use. The newfound understanding of TXA2’s role in immune suppression will help interpret trial results and refine treatment protocols.

The scientific community is optimistic about translating these findings into real-world applications. The discovery represents a significant step forward in understanding how the immune system can be harnessed to prevent metastasis—a major challenge in cancer treatment. As researchers continue to unravel the intricacies of this mechanism, there is hope that it will lead not only to more effective drugs but also to personalised approaches tailored to individual patient profiles.

This breakthrough underscores the importance of investigating widely-used drugs like aspirin for unexpected benefits beyond their primary applications. The serendipitous nature of the discovery highlights how curiosity-driven research can yield transformative insights with far-reaching implications for human health.

Aspirin’s potential as an anti-metastatic agent could change how doctors approach cancer treatment and prevention. By targeting TXA2-mediated suppression of T cells, it offers a novel strategy to combat the spread of susceptible cancers during their most vulnerable stage. As clinical trials progress and further research refines these findings, the future looks brighter for patients facing the daunting prospect of cancer recurrence.